Collegium Pharmaceutical

Recent news

• Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Cuts Target Price to $48
  Market Newswire · 2026/8/19
• Rating change
  A Quick Look at Today's Ratings for Collegium Pharmaceutical(COLL.US), With a Forecast Between $44 to $60
  Market Newswire · 2026/3/20
• H.C. Wainwright Reaffirms Their Buy Rating on Collegium Pharmaceutical (COLL)
  TipRanks · 2026/9/22
• H.C. Wainwright Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $60
  Market Newswire · 2026/9/22
• Company notice
  Malayan Banking: Malayan Banking Berhad ("Maybank" or "the Company") . Proposed Establishment of a New Employee Share Option Scheme ("Proposed ESOS") . Proposed Amendments to the Articles of Association of Maybank ("Proposed Amendments") (to be coll
  Bursa Malaysia · 2004/1/26
• Rating change
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL), Myriad Genetics (MYGN) and Mineralys Therapeutics, Inc. (MLYS)
  TipRanks · 2026/5/8
• Rating change
  Piper Sandler Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating, Maintains Target Price $44
  Market Newswire · 2026/4/23
• Rating change
  Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $58
  Market Newswire · 2026/2/27
• Truist Financial Initiates Collegium Pharmaceutical(COLL.US) With Buy Rating, Announces Target Price $49
  Market Newswire · 2026/9/9
• Company notice
  AWC: AWC FACILITY SOLUTIONS BERHAD ("AWC" or the "Company") . PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION OF AWC ("PROPOSED AMENDMENT"); AND . PROPOSED ESTABLISHMENT OF AN EMPLOYEE SHARE OPTION SCHEME ("PROPOSED ESOS") (COLL
  Bursa Malaysia · 2004/4/27
• Leerink Partners Initiates Collegium Pharmaceutical(COLL.US) With Buy Rating, Announces Target Price $45
  Market Newswire · 2026/9/9
• Company notice
  Majuperak Holdings: UNITED CHEMICAL INDUSTRIES BERHAD (UCI or Company) . Proposed UCI Scheme . Proposed Harta Perak Acquisition . Proposed Majuperak Scheme . Proposed Transfer of Listing Status . Proposed Public Issue . Proposed Offer for Sale (coll
  Bursa Malaysia · 2003/4/10
• Rating change
  Piper Sandler Maintains Collegium Pharmaceutical(COLL.US) With Hold Rating, Cuts Target Price to $43
  Market Newswire · 2026/8/7
• Rating change
  Needham Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $56
  Market Newswire · 2026/5/13
• Rating change
  Needham Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Cuts Target Price to $46
  Market Newswire · 2026/8/7
• Rating change
  Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $56
  Market Newswire · 2026/7/1
• Rating change
  H.C. Wainwright Sticks to Its Buy Rating for Collegium Pharmaceutical (COLL)
  TipRanks · 2026/4/24
• Rating change
  Needham Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Cuts Target Price to $54
  Market Newswire · 2026/2/27
• Rating change
  Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating
  Market Newswire · 2026/5/15
• Rating change
  Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Sionna Therapeutics, Inc. (SION)
  TipRanks · 2026/5/13

Headlines are aggregated automatically and are not independently verified or edited by our team.